HC Wainwright Adjusts Price Target for Aardvark Therapeutics
HC Wainwright has lowered its price target for Aardvark Therapeutics from $4.00 to $2.00 while maintaining a Neutral rating.
Stocks · News reference
Aardvark Therapeutics Reports Exploratory Data from Terminated HERO and OLE Trials
Aardvark Therapeutics released exploratory efficacy and safety data from its previously terminated Phase 3 HERO and open-label extension trials for ARD-101.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
FDA Lifts Clinical Hold on Aardvark Therapeutics' ARD-101
The U.S. Food and Drug Administration has lifted the clinical hold on Aardvark Therapeutics' investigational new drug application for ARD-101, intended for treating hyperphagia in Prader-Willi Syndrome.
8-K filing — Aardvark Therapeutics, Inc. (AARD)
Filed: 2026-10-23 AccNo: 0001193125-26-429509 Size: 11 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits